A Tale Of Two Advisory Panels: The Divergent Fates Of Pretomanid And Plazomicin

 
• By Michael Cipriano

The TB Alliance and Achaogen both presented their drugs to US FDA's Antimicrobial Drugs Advisory Committee with small patient populations in pivotal trials. Why did one fare better than the other?

view of three wooden directional signs on a pole - Image
Panelists went in different directions when voting on approval for the two drugs.

More from US FDA Performance Tracker

More from Regulatory Trackers